Marker Therapeutics Inc (MRKR)

[Phantom Lord]

I believe they are only mentioning the 20 patients enrolled by the end of the year because that will be the data set they will be reporting the interim results on in Q1 next year. Officially, it makes sense that they would not give a timeline on when they expect full enrollment as there are many things that can come up that cause delays. It's one thing for them to announce next year that there was a delay in enrollment but another for them to announce next year that there was a delay in enrollment when they already stated enrollment would be complete by the end of this year. This statement of 20 patients enrolled by the end of this year is not new. They have been stating this for the past few months. Per prior communication with the company and reading a bit between the lines I believe that enrollment of the active group should be complete around the end of Q1 next year with a full readout on the active group sometime mid year. If this timeline holds the BLA filing could then come by the end of next year for the active group. The adjuvant group is larger and they have not provided official guidance on enrollment timelines but I believe Dr. Koneru said in her last presentation that full enrollment in that group could be reached by the end of next year. They've been opening up new trial sites over the past few months and have a few more to get open so enrollment should only pick up as new sites are added.

Are Doctors NOT recommending Marker trials for AML and Pancreatic and if so, why?

There is no actively enrolling trial in pancreatic so they can't recommend that. I expect this to change soon with a Marker sponsored pancreatic trial being initiated hopefully sometime next year. We'll see how this plays out as I have already touched on this in a previous post.

As for the AML trial there are a lot of things to take into account. Per the company's corporate presentation the patient group they are targeting is roughly 3,500 per year. Not all of those patients are even going to be eligible for the trial so that so that only limits it further. On top of that not everyone is comfortable taking part in a clinical trial. All this aside I believe it's a fairly safe bet to assume full enrollment by the end of next year or Q1 of 2023.